This clinical quandary discusses oligoprogressive disease in metastatic melanoma and how treatment with immunotherapy and targeted therapy affect the disease.
Diego López-Macías, MD
Advertisement
Articles by Diego López-Macías, MD
Advertisement
Latest Updated Articles
Oligoprogression After Immunotherapy and Targeted Therapy in Metastatic MelanomaPublished: September 16th 2021 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Adjuvant Therapy Confers Postoperative ctDNA Clearance, DFS Benefit in CRC
2
Sacituzumab Tirumotecan Improves Survival in Second-Line EGFR+ NSCLC
3
TUB-040 Elicits Early Responses in Platinum-Resistant Ovarian Cancer
4
Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm
5
